Table 1.
Characteristics of study participants who completed screening. Values are numbers (percentages) unless stated otherwise
| Characteristic | Value (n=229) |
|---|---|
| Mean (SD) age (years): | |
| At transplant | 52.6 (10.3) |
| At screening | 61.5 (6.9) |
| Male sex | 151 (66) |
| Time since transplant (years): | |
| <5 | 97 (42) |
| 5-10 | 57 (25) |
| 10-15 | 35 (15) |
| 15-20 | 16 (7) |
| >20 | 24 (10) |
| Mean (SD) | 9.0 (8.4) |
| Median | 6.5 |
| Renal function: | |
| Mean (SD) serum creatinine (µmol/L) | 122.2 (47.3) |
| Mean (SD) MDRD eGFR (mL/min/1.73 m2) | 55.1 (19.3) |
| Cause of end stage kidney disease: | |
| Glomerulonephritis | 127 (55) |
| Polycystic kidney disease | 32 (14) |
| Diabetic nephropathy | 20 (9) |
| Hypertension | 8 (3) |
| Other | 36 (16) |
| Unknown | 6 (3) |
| Deceased donor | 189 (83) |
| Second or subsequent transplant | 29 (13) |
| Immunosuppressive drugs at time of screening: | |
| Triple—ciclosporin based (+ MMF/azathioprine and steroids) | 24 (10) |
| Triple—tacrolimus based (+ MMF/azathioprine and steroids) | 53 (23) |
| Triple—mTOR inhibitor based (+ MMF/azathioprine and steroids) | 45 (20) |
| Dual—ciclosporin based (+ MMF/azathioprine) | 35 (15) |
| Dual—tacrolimus based (+ MMF/azathioprine) | 12 (5) |
| Dual—mTOR inhibitor (+ MMF/azathioprine) | 10 (4) |
| Dual—MMF/azathioprine + steroids | 25 (11) |
| Other (including steroid or MMF alone, experimental agents) | 21 (9) |
| Not on immunosuppression at time of screening | 1 (<1) |
| Not recorded | 1 (<1) |
| Current or former smoker | 86 (38) |
| History of other significant medical conditions: | |
| Cardiovascular disease | 93 (41) |
| Diabetes | 81 (35) |
| Chronic lung disease | 23 (10) |
| Previous malignancy: | |
| Non-melanoma skin cancer (SCC or BCC) | 75 (33) |
| Other* | 20 (9) |
| Antiplatelet or anticoagulant drug use: | |
| Aspirin | 69 (30) |
| Clopidogrel | 8 (3) |
| Warfarin | 19 (8) |
BCC=basal cell carcinoma; MDRD eGFR=glomerular filtration rate estimated using four variable modification of diet in renal disease equation; MMF=mycophenolic acid derivative (mycophenolate mofetil or mycophenolic acid sodium); mTOR inhibitor=mammalian target of rapamycin inhibitor (sirolimus or everolimus); SCC=squamous cell carcinoma.
*Melanoma (n=4); prostate (n=4); bladder (n=3); cervical (n=2); head and neck (n=2); renal (n=2); endometrium (n=1); breast (n=1); lymphoma (n=1); leukaemia (n=1).